Cascade Chemistry Initiates Expansion of cGMP Manufacturing Capacity

Cascade Chemistry announced initiation of construction of new facilities designed to increase the company’s capacity to manufacture APIs (active pharmaceutical ingredients) under cGMP (current Good Manufacturing Practices standards and procedures).

The new facilities, expected to be operational in the first quarter of 2022, will increase the company’s floor space almost three-fold and add to its cGMP manufacturing capacity and scale. The expansion also includes 2,200 square feet of new analytical labs, a robust quality system and additional office space.

“This $14 million expansion reflects our growing success as a reliable, experienced and flexible outsourcing partner with exceptional chemistry problem-solving expertise,” said Jeremiah Marsden, PhD, President of Cascade Chemistry. “Our customers are increasingly requesting our assistance in producing APIs for their clinical trials, and demand has outstripped our cGMP manufacturing capacity. We were fortunate to acquire two suitable buildings just 10 minutes from our current facility, and construction of new cGMP manufacturing suites that will greatly increase our clinical trial API production capacity is now underway.”

The 28,000-square-foot building currently under construction will initially include five suites for Phase 1 and Phase 2 cGMP manufacturing with flow hydrogenation and reactors up to 400 liters. Additional capacity for API Phase 3 and commercial scale cGMP manufacturing up to 1,000 liters will be added in 2022. The second building, with 7,000 square feet, is reserved for future expansion.